Information Provided By:
Fly News Breaks for August 7, 2017
Aug 7, 2017 | 07:56 EDT
As previously reported, Morgan Stanley downgraded Teva to Underweight from Equal Weight and cut its price target to $16 from $36. Analyst David Risinger said he underappreciated generic pricing pressure risks on Teva's dividend and expects declining earnings power, combined with high leverage equal to result in a longer recovery. He expects core business generic headwinds and Copaxone generic competition to pressure Teva's long-term earnings power and cut his 2017 earnings estimate to $1.24 from $1.55, 2018 earnings estimate to $4.14 from $4.56, and 2019 earnings estimate to $3.79 from $4.50. Risinger's bear case price target on Teva is $9, which assumes much more severe Copaxone erosion and generic business downside.
News For TEVA From the Last 2 Days
There are no results for your query TEVA